Jonathan Serody, MD, explains in a two-minute video the action behind chimeric antigen T-cell, or CAR-T, immunotherapy and how UNC Lineberger is designing, developing and delivering CAR-T therapies to treat cancers that fail to respond to standard treatments.
The multi-institutional team, which is co-led by UNC Lineberger’s Gianpietro Dotti, MD, and includes six UNC Lineberger researchers, will focus on developing chimeric antigen receptor T-cell (CAR-T) therapies to recognize and attack T-cell lymphoma, a group of rare cancers of the blood and immune system.
A team led by UNC Lineberger’s Gianpietro Dotti, MD, has engineered immune cells to hunt glioblastoma, the most lethal primary brain tumor. They presented their findings in Science Translational Medicine.
Seeking to help in the development of treatments for metastatic cancer, Alice Lehman of Charlotte has donated $4 million to further the work of UNC Lineberger’s new cellular immunotherapy research program.